Author: Shan Gao1, Xixiu Ni1, Zhenxi He1, Yanan Wang1, Mingsheng Sun1,2, Lu Liu1, Yang Yu1, Qing Liu1, Xingyu Chen1, Jianwei Wu3, Ling Zhao1,2
Affiliation: <sup>1</sup> Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
<sup>2</sup> Clinical Research Center for Acupuncture and Moxibustion in Sichuan Province, Chengdu, China.
<sup>3</sup> Chinese Classics School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Conference/Journal: Evid Based Complement Alternat Med
Date published: 2021 Jun 21
Other:
Volume ID: 2021 , Pages: 9932336 , Special Notes: doi: 10.1155/2021/9932336. , Word Count: 254
Background. Chronic primary musculoskeletal pain (CPMP) is a major health problem that has physical and psychological impacts as well as an associated economic burden. Currently, pharmacological treatment remains unsatisfactory because of side effects and potential misuse. Therefore, nonpharmacological approaches for pain are being actively explored, and Tai Chi has attracted increased attention as a therapy for pain. Although clinical trials have shown that Tai Chi may be effective in treating CPMP, no systematic review has clarified its effectiveness and safety. The objective of this systematic review is to assess the effect and safety of Tai Chi for patients suffering from CPMP. Methods and Analysis. We will search relevant electronic databases from inception to May 31, 2021: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, the Wanfang database, the Chongqing VIP database, and China Biology Medicine Disc. Studies comparing the use of Tai Chi with other managements for CPMP patients will be included. Our review will include studies that measured change in pain intensity as the primary outcome using patient-reported ratings (visual analog scale or numerical rating scale). Hospital Anxiety and Depression Scale scores, SF-36 Health Survey scores, Pittsburgh Sleep Quality Index scores, and adverse effects will be explored as secondary outcomes. The risk of bias and the reporting quality of included studies will be evaluated using the Cochrane Collaboration risk-of-bias assessment method. The data will be analyzed using RevMan v5.3 software. Study Registration. This study protocol was registered on PROSPERO. The registration number for this protocol is CRD42020165048.
PMID: 34249134 PMCID: PMC8238584 DOI: 10.1155/2021/9932336